KRAS and cancer: Given the recent advances in clinical trials to directly target KRAS and GNAS mutations in other cancers, we propose a rationale to explore targeting KRAS G12C and G12D, and GNAS R201H and R201C in pre-clinical studies in PMP to produce preliminary results supporting a future clinical trial.